Project description
Single-cell metabolomics technology for prevention of adverse drug reactions
A major source of failure in drug development is an adverse drug reaction caused by off-target effects of drug candidates, often revealed late in the development process. Metabolomics represents a promising emerging approach to monitoring off-target effects on metabolic enzymes, providing a mechanistic understanding of drug toxicity. The challenges in metabolomics applications include the inability to resolve the drug metabolic response at single-cell level. The ERC-funded METADRUG project aims to commercialise the previously developed single-cell metabolomics. The goal is to use single-cell technology together with the data-driven metabolic modulation approach for the evaluation of single-cell metabolic response to drugs and drug candidates.
Objective
Despite the major efforts in the modern drug discovery and development, the field is still in its crisis with the productivity increasingly declining. A major source of drug development failure is the toxicity where the adverse drug reaction is often caused by off-target effects of drug candidates that can be revealed only late in the drug development process. Metabolomics was proposed as an emerging promising approach to monitor off-targets effects on metabolic enzymes or transporters thus providing mechanistic understanding of drug toxicity. However, there are multiple challenges in applying metabolomics in this context including the inability to resolve the drug metabolic response on the single-cell level. In this PoC project, we propose to commercialize the technology of single-cell metabolomics developed in the ERC CoG project METACELL. Specifically, we propose using our single-cell metabolomics technology in conjunction with the data-driven metabolic modulation approach for revealing single-cell metabolic response and metabolic mode of action of drugs and drug candidates.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- social scienceseconomics and businesseconomicsproduction economicsproductivity
- medical and health sciencesbasic medicinepharmacology and pharmacyadverse drug reactions
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsenzymes
Programme(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Funding Scheme
HORIZON-AG-LS - HORIZON Lump Sum GrantHost institution
69117 Heidelberg
Germany